Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

Allos presents phase Ib results of RSR-13 in patients with angina

March 24, 1999

Kyowa Hakko and Cor select development candidates for inhibiting PDGF receptor phosphorylation

March 24, 1999

Integrin receptor antagonists disclosed by SB

March 24, 1999

SB-247083: design of a selective, orally active ETA antagonist

March 23, 1999

ABT-627 now being evaluated in humans

March 23, 1999

Endothelin receptor antagonists for cardiovascular, renal and cerebral disorders

March 22, 1999

News from ASCPT: first report of clinical evaluation of Schwarz's organic nitrate

March 22, 1999

Gliatech initiates new R&D program for antiinflammatory MAbs

March 19, 1999

Pharmacological profile of A-216546, a novel endothelin antagonist

March 19, 1999

Cardiovascular and Renal Drugs Advisory Committee will discuss Betapace at April meeting

March 19, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...